Figure 3.
The Kaplan-Meier survival curves of ADA continuation. Patients with ADA and IM were significantly more likely to keep higher persistence of ADA compared to those with ADA monotherapy. ADA: adalimumab, IM: immunomodulator
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.